Overview

The Global Anti-Inflammatory Therapeutics Market has substantially surpassed previous forecasts. The market size, which was projected to reach $106.1 billion by 2020, is currently estimated to be valued between US$109.58 billion and US$120.37 billion in 2025. The market is now projected to grow at a strong Compound Annual Growth Rate (CAGR) ranging from 4.14% to 7.89% over the forecast period (2025–2030/2034), indicating sustained and accelerated market momentum driven by therapeutic innovation.

According to the World Health Organization (WHO) and other global health initiatives, the burden of inflammatory diseases remains critical. Symptomatic relief and disease modification during the inflammatory process remain vital for patients suffering from a wide range of chronic inflammatory and autoimmune diseases.
Although there are multiple anti-inflammatory drugs approved in the market, there remains an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and superior efficacy. This need is fueling the massive investment into next-generation therapies.

The global anti-inflammatory market is being driven by factors such as the increasing prevalence of autoimmune and respiratory conditions (including rheumatoid arthritis, psoriasis, and inflammatory bowel disease), a highly robust new drug pipeline (especially in biologics and targeted small molecules like JAK inhibitors), and the increasing global adoption of advanced anti-inflammatory therapies.

Moreover, increasing patient and physician awareness of anti-inflammatory therapeutics, combined with attractive government and healthcare initiatives (especially toward improving access to specialty drugs in emerging markets like the Asia-Pacific and LAMEA region), are expected to continue driving the market during the analysis period.